Studies

84.8% of older adults reported general improvement after 6 months; mild adverse events (dizziness, drowsiness). See the source and access in Brazil.

Review of efficacy, safety and precautions (polypharmacy, cardiovascular risk) in use by older adults. See the source and access in Brazil.

Systematic review of medical cannabinoids in older populations. See the source and access in Brazil.

Meta-analysis: association with adverse neonatal outcomes (preterm birth, low weight). Guidelines advise against use. See the source and access in Brazil.

Review: prenatal exposure associated with impacts on fetal and child development. Use advised against. See the source and access in Brazil.

Attention to cannabinoid hyperemesis syndrome (paradoxical effect); guidance against use in pregnancy. See the source and access in Brazil.

Double-blind RCT: CBD effective and safe in mild to moderate anxiety and in associated depression and sleep symptoms. See the source and access in Brazil.

Pilot study: adjunctive CBD in bipolar depression (negative primary outcome; suggests studying doses ≥300 mg/day). See the source and access in Brazil.

Randomized, double-blind, placebo-controlled trial of a CBD-rich cannabis extract in children with autism. See the source and access in Brazil.

Placebo-controlled study (150 children/adolescents with ASD) assessing sleep parameters via the CSHQ scale. See the source and access in Brazil.

Improvement in spasticity, dystonia, sleep, pain and quality of life in children with complex motor disorders. See the source and access in Brazil.

Case series on the use of medical cannabis in children under palliative care. See the source and access in Brazil.

Retrospective review of the use of oral cannabis extracts in the pediatric palliative-care setting. See the source and access in Brazil.

Phase 3 RCT (212 children/adolescents): significant behavioral improvement in the subgroup with ≥90% FMR1 methylation. See the source and access in Brazil.

Open-label use of purified CBD in rare syndromes: ~51–59% reduction in convulsive seizures over 12–48 weeks. See the source and access in Brazil.

RCT (GWPCARE6): CBD reduced resistant seizures associated with tuberous sclerosis complex. See the source and access in Brazil.

Cohort of 74 children/adolescents: 89% seizure reduction with CBD-rich cannabis (retrospective study). See the source and access in Brazil.

Crossover RCT (Epidiolex up to 20 mg/kg/day): improvement in socialization and anxiety; safety assessed. See the source and access in Brazil.

Retrospective feasibility study (Aran et al.): reported behavioral improvement in children with autism. See the source and access in Brazil.

Crossover RCT: benefits in anxiety and social relations and reduced parental stress (primary outcome not met). See the source and access in Brazil.

Double-blind RCT (53 children/adolescents, CBD:THC 10:1): well tolerated and safe; no significant spasticity difference vs placebo

Review and meta-analysis of cannabinoids for nausea, pain and other symptoms in pediatric oncology. See the source and access in Brazil.

Crossover RCT (16 patients): inhaled cannabis reduced diabetic neuropathy pain in a dose-dependent manner. See the source and access in Brazil.

Phase III, double-blind RCT (100 participants): transdermal THC:CBD:CBN formula in pain management. See the source and access in Brazil.

Prospective study: nabiximols in chronic spinal cord injury spasticity refractory to conventional therapy. See the source and access in Brazil.

Trial on vaporized cannabis in the treatment of pain associated with spinal cord injury. See the source and access in Brazil.

RCT (78 adults): CBD 800 mg/day vs placebo for craving and relapse prevention in cocaine use. See the source and access in Brazil.

Double-blind exploratory study on CBD for crack-cocaine craving. See the source and access in Brazil.

RCT (50 patients): smoked cannabis reduced pain by 34% vs 17% with placebo in HIV neuropathy. See the source and access in Brazil.

Crossover RCT: smoked cannabis reduced HIV-associated neuropathic pain refractory to other treatments. See the source and access in Brazil.

Survey (women ≥35 years): patterns and perceptions of cannabis use for menopause symptoms. See the source and access in Brazil.

Qualitative study: cannabis reported as relieving symptoms in the menopause transition. See the source and access in Brazil.

Double-blind pilot RCT: THCV improved glycemic control in patients with type 2 diabetes. See the source and access in Brazil.

Review of the use of CBD in metabolic syndrome — potential effects and limitations. See the source and access in Brazil.

Phase II RCT: dronabinol reduced the apnea-hypopnea index (AHI) and daytime sleepiness in OSA. See the source and access in Brazil.

Proof-of-concept study on dronabinol in the treatment of obstructive sleep apnea. See the source and access in Brazil.

Scoping review of cannabinoids in SARS-CoV-2 infection and in long-COVID symptoms. See the source and access in Brazil.

Critical review of the use of cannabinoids in headaches (migraine and cluster headache). See the source and access in Brazil.

RCT (58 patients, 5 weeks): analgesic effect and suppression of disease activity with Sativex in RA. See the source and access in Brazil.

Reported improvement in pain (83%), physical function (66%) and sleep quality (66%) with CBD in arthritis. See the source and access in Brazil.

Review of the role of the endocannabinoid system in irritable bowel syndrome and the potential of cannabis. See the source and access in Brazil.

Retrospective cohort on the association between cannabis use and health outcomes/utilization in IBS. See the source and access in Brazil.

6-week RCT (Sativex) evaluating cognition and symptoms in adults with ADHD. See the source and access in Brazil.

Study on the therapeutic reasons reported for cannabis use in people with ADHD. See the source and access in Brazil.

Review of the anti-inflammatory and neuroprotective effects of cannabinoids in traumatic brain injury. See the source and access in Brazil.

Study on the clinical outcomes of traumatic brain injury associated with cannabis use. See the source and access in Brazil.

Review of cannabinoids and intraocular pressure reduction in glaucoma (short-lived effect). See the source and access in Brazil.

Review: synthetic cannabinoids (dronabinol/nabilone) showed benefit in agitation and aggression in AD. See the source and access in Brazil.

Randomized, double-blind, placebo-controlled feasibility trial of nabiximols in UK care homes. See the source and access in Brazil.

Double-blind RCT: a single dose of CBD 800 mg reduced alcohol craving and nucleus accumbens activation. See the source and access in Brazil.

Pilot study: on-demand CBD reduced the number of cigarettes smoked by ~40% vs placebo. See the source and access in Brazil.

Observational study: improvement in itching and dermatitis with a topical cannabinoid gel. See the source and access in Brazil.

Scoping review of cannabinoids in acne, atopic dermatitis, psoriasis and pruritus. See the source and access in Brazil.

Double-blind placebo-controlled trial of THC:CBD 1:1 oil for symptoms in advanced cancer. See the source and access in Brazil.

Systematic review: effects on pain, nausea/vomiting, appetite, sleep and fatigue (low evidence quality). See the source and access in Brazil.

Review of 9 studies: cannabis as an adjuvant may reduce the opioid dose in non-cancer chronic pain. See the source and access in Brazil.

Study with 186 patients: reduced opioid prescribing and improved pain and disability in low back pain. See the source and access in Brazil.

Reduction of PTSD symptoms, including nightmares, with CBD adjuvant to routine psychiatric care. See the source and access in Brazil.

Randomized pilot trial combining CBD with prolonged exposure therapy in PTSD. See the source and access in Brazil.

RCT (McGuire et al.): CBD 1000 mg/day reduced positive psychotic symptoms vs placebo, with good tolerability. See the source and access in Brazil.

Randomized placebo-controlled trial on the effect of CBD on cognition and symptoms of schizophrenia. See the source and access in Brazil.

Study with 252 participants: cannabis was associated with reduced pelvic pain and endometriosis-related symptoms. See the source and access in Brazil.

Review of 9 studies (1,787 participants): pain was the most common indication for cannabis use. See the source and access in Brazil.

Intervention to prevent youth access to cannabis. See the source and access in Brazil.

Parent intervention to reduce cannabis use among college students. See the source and access in Brazil.

Evaluates cannabidiol in severe acute graft-versus-host disease (GvHD). See the source and access in Brazil.

Phase 2a study of the safety and efficacy of cannabidiol in autoimmune hepatitis. See the source and access in Brazil.

Evaluates cannabidiol in controlling dental pain (toothache). See the source and access in Brazil.

Studies a CBD candy in reducing tooth-decay-causing bacteria. See the source and access in Brazil.

Evaluates CBD isolate in relieving menstrual-related symptoms. See the source and access in Brazil.

Investigates cannabis effects on visual functions (retinitis pigmentosa). See the source and access in Brazil.

Compares smoked and oral cannabis in people living with HIV/AIDS. See the source and access in Brazil.

Studies cannabidiol interactions with the CES1 enzyme in healthy volunteers. See the source and access in Brazil.

Evaluates the pharmacokinetics and effects of a standardized cannabis preparation. See the source and access in Brazil.

Pharmacokinetic evaluation of a natural cannabidiol (CBD) extract. See the source and access in Brazil.

Review of controlled and observational studies; more consistent effect in neuropathic pain. See the source and access in Brazil.

Meta-analysis of randomized controlled trials on the analgesic effect of cannabinoids. See the source and access in Brazil.

Low-strength evidence for neuropathic pain relief, with an overview of potential harms. See the source and access in Brazil.

Concludes that cannabis is moderately effective in treating chronic pain. See the source and access in Brazil.

Clinical trial on the use of cannabidiol (CBD) in chronic pain management. See the source and access in Brazil.

Evaluates the combination of THC and CBD in chronic pain associated with opioid use disorder. See the source and access in Brazil.

Investigates cannabinoid tablets in relieving knee osteoarthritis pain. See the source and access in Brazil.

Studies Sativex (THC:CBD) in chemotherapy-induced neuropathic pain. See the source and access in Brazil.

Evaluates the efficacy and tolerability of AP707 (cannabis) in chronic central neuropathic pain. See the source and access in Brazil.

Examines cannabis use, strength training and alcohol in people with chronic pain. See the source and access in Brazil.

Quantifies cannabinoids and compares with the need for analgesics after cancer surgery. See the source and access in Brazil.

Evaluates the safety and effects of natural medical cannabis on stress and pain responses. See the source and access in Brazil.

Landmark RCT: significant reduction in convulsive seizures vs placebo (Devinsky et al.). See the source and access in Brazil.

RCT: ~42% reduction in drop seizures with cannabidiol 20 mg/kg/day. See the source and access in Brazil.

Treats refractory epilepsy associated with tuberous sclerosis with full-spectrum cannabis extract. See the source and access in Brazil.

Evaluates a cannabidiol oral solution in children with treatment-resistant seizures. See the source and access in Brazil.

Nabiximols reduces spasticity in patients with multiple sclerosis. See the source and access in Brazil.

Confirms the benefit of nabiximols as an adjuvant therapy in spasticity. See the source and access in Brazil.

Compares Sativex vs placebo in central neuropathic pain of multiple sclerosis. See the source and access in Brazil.

Transcranial stimulation (tDCS) via telehealth to reduce cannabis use in people with MS. See the source and access in Brazil.

Cannabinoids superior to conventional antiemetics of the time (Tramèr et al.). See the source and access in Brazil.

Cochrane review: higher chance of complete absence of nausea and vomiting. See the source and access in Brazil.

Evaluates the effect of cannabinoids on appetite and weight in oncology patients. See the source and access in Brazil.

A comprehensive, updated National Cancer Institute summary on cannabis in oncology. See the source and access in Brazil.

Evaluates the use of cannabidiol (CBD) in cancer patients. See the source and access in Brazil.